Last reviewed · How we verify
refractory anemia ra
Approved treatments
Clinical guidelines
- FDA label — 1L
Azacitidine for injection is indicated for the treatment of adult patients with refractory anemia (RA). - FDA label — 1L
Azacitidine for injection is indicated for the treatment of adult patients with refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions. - FDA label — 1L
Azacitidine for injection is indicated for the treatment of adult patients with refractory anemia with excess blasts (RAEB). - FDA label — 1L
Azacitidine for injection is indicated for the treatment of adult patients with refractory anemia with excess blasts in transformation (RAEB-T). - FDA label — 1L
Azacitidine for injection is indicated for the treatment of adult patients with chronic myelomonocytic leukemia (CMMoL).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- refractory anemia ra patent landscape — cliff calendar, originator estates, attackable patents
- refractory anemia ra treatment landscape brief
- refractory anemia ra treatment updates RSS
Frequently asked questions about refractory anemia ra
What are the treatment guidelines for refractory anemia ra?
FDA label publishes guidelines for refractory anemia ra. 5 guideline references tracked.
Related
- Treatment landscape: refractory anemia ra patent cliff · refractory anemia ra CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing